Pralatrexate for refractory mycosis fungoides in two Japanese patients

Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced‐stage cutaneous T‐cell lymphomas, but outcomes in Japanese patients have not yet been reported. We herein desc...

Descripción completa

Detalles Bibliográficos
Autores principales: Teraishi, Mika, Oguro, Tokuko, Kusume, Ema, Kobashi, Haruka, Sano, Hozumi, Fujioka, Ai, Yamamoto, Mayuko, Nakajima, Hideki, Sano, Shigetoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Concise Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248132/
https://www.ncbi.nlm.nih.gov/pubmed/33454985
http://dx.doi.org/10.1111/1346-8138.15761
_version_ 1783716662813392896
author Teraishi, Mika
Oguro, Tokuko
Kusume, Ema
Kobashi, Haruka
Sano, Hozumi
Fujioka, Ai
Yamamoto, Mayuko
Nakajima, Hideki
Sano, Shigetoshi
author_facet Teraishi, Mika
Oguro, Tokuko
Kusume, Ema
Kobashi, Haruka
Sano, Hozumi
Fujioka, Ai
Yamamoto, Mayuko
Nakajima, Hideki
Sano, Shigetoshi
author_sort Teraishi, Mika
collection PubMed
description Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced‐stage cutaneous T‐cell lymphomas, but outcomes in Japanese patients have not yet been reported. We herein describe two Japanese patients with heavily‐pretreated relapsed/refractory mycosis fungoides that were successfully controlled by pralatrexate.
format Online
Article
Text
id pubmed-8248132
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82481322021-07-02 Pralatrexate for refractory mycosis fungoides in two Japanese patients Teraishi, Mika Oguro, Tokuko Kusume, Ema Kobashi, Haruka Sano, Hozumi Fujioka, Ai Yamamoto, Mayuko Nakajima, Hideki Sano, Shigetoshi J Dermatol Concise Communications Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced‐stage cutaneous T‐cell lymphomas, but outcomes in Japanese patients have not yet been reported. We herein describe two Japanese patients with heavily‐pretreated relapsed/refractory mycosis fungoides that were successfully controlled by pralatrexate. John Wiley and Sons Inc. 2021-01-16 2021-05 /pmc/articles/PMC8248132/ /pubmed/33454985 http://dx.doi.org/10.1111/1346-8138.15761 Text en © 2021 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Concise Communications
Teraishi, Mika
Oguro, Tokuko
Kusume, Ema
Kobashi, Haruka
Sano, Hozumi
Fujioka, Ai
Yamamoto, Mayuko
Nakajima, Hideki
Sano, Shigetoshi
Pralatrexate for refractory mycosis fungoides in two Japanese patients
title Pralatrexate for refractory mycosis fungoides in two Japanese patients
title_full Pralatrexate for refractory mycosis fungoides in two Japanese patients
title_fullStr Pralatrexate for refractory mycosis fungoides in two Japanese patients
title_full_unstemmed Pralatrexate for refractory mycosis fungoides in two Japanese patients
title_short Pralatrexate for refractory mycosis fungoides in two Japanese patients
title_sort pralatrexate for refractory mycosis fungoides in two japanese patients
topic Concise Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248132/
https://www.ncbi.nlm.nih.gov/pubmed/33454985
http://dx.doi.org/10.1111/1346-8138.15761
work_keys_str_mv AT teraishimika pralatrexateforrefractorymycosisfungoidesintwojapanesepatients
AT ogurotokuko pralatrexateforrefractorymycosisfungoidesintwojapanesepatients
AT kusumeema pralatrexateforrefractorymycosisfungoidesintwojapanesepatients
AT kobashiharuka pralatrexateforrefractorymycosisfungoidesintwojapanesepatients
AT sanohozumi pralatrexateforrefractorymycosisfungoidesintwojapanesepatients
AT fujiokaai pralatrexateforrefractorymycosisfungoidesintwojapanesepatients
AT yamamotomayuko pralatrexateforrefractorymycosisfungoidesintwojapanesepatients
AT nakajimahideki pralatrexateforrefractorymycosisfungoidesintwojapanesepatients
AT sanoshigetoshi pralatrexateforrefractorymycosisfungoidesintwojapanesepatients

Ejemplares similares